Valuation: Celltrion, Inc.

Market Cap 42,815B 29.8B 25.77B 24.06B 22.05B 41.62B 2,843B 42.26B 283B 111B 1,416B 112B 109B 4,685B P/E 2026 *
28.4x
P/E 2027 * 24.5x
Enterprise Value 44.79B 31.18M 26.97M 25.17M 23.07M 43.54M 2.97B 44.21M 296M 116M 1.48B 117M 115M 4.9B EV / Sales 2026 *
8.22x
EV / Sales 2027 * 6.97x
Free-Float
58.02%
Yield 2026 *
0.41%
Yield 2027 * 0.44%
Manager TitleAgeSince
Chief Executive Officer 65 19/03/2015
Chief Executive Officer 42 25/03/2021
President 50 12/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 31/03/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
-0.90%+2.62%+37.06%+10.96% 11.2B
Average -1.40%+0.85%+62.86%+98.89% 25.76B
Weighted average by Cap. -1.54%+1.75%+84.09%+133.35%

Financials

2026 *2027 *
Net sales 5,449B 3.79B 3.28B 3.06B 2.81B 5.3B 362B 5.38B 35.98B 14.13B 180B 14.24B 13.93B 596B 6,325B 4.4B 3.81B 3.55B 3.26B 6.15B 420B 6.24B 41.76B 16.4B 209B 16.53B 16.17B 692B
Net income 1,485B 1.03B 894M 835M 765M 1.44B 98.62B 1.47B 9.81B 3.85B 49.12B 3.88B 3.8B 163B 1,768B 1.23B 1.06B 994M 911M 1.72B 117B 1.75B 11.67B 4.58B 58.47B 4.62B 4.52B 194B
Net Debt 1,978B 1.38B 1.19B 1.11B 1.02B 1.92B 131B 1.95B 13.06B 5.13B 65.4B 5.17B 5.06B 216B 1,262B 879M 760M 710M 650M 1.23B 83.83B 1.25B 8.33B 3.27B 41.75B 3.3B 3.23B 138B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A